Haikang Zhao1,2, Xin Wang3, Xiaoyun Feng3, Xiaoqiang Li2, Li Pan1, Jianrong Liu2, Fenglu Wang2, Zhihai Yuan2, Lei Yang2, Jun Yu4, Rujuan Su5, Yuelin Zhang6, Lianting Ma7. 1. Department of Neurosurgery, Wuhan General Hospital of PLA, No. 627 Wuluo Road, Wuhan, 430070, Hubei, China. 2. Department of Neurosurgery, The Second Affiliated Hospital, Xi'an Medical University, Xi'an, 710038, Shaanxi, China. 3. Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China. 4. Experimental Center, The Second Affiliated Hospital, Xi'an Medical University, Xi'an, 710038, Shaanxi, China. 5. Department of Oncology, First Affiliated Hospital of Medical College of Xi'an Jiaotong University, No. 277 Yanta west Road, Xi'an, 710061, Shaanxi, China. rujuansu@163.com. 6. Shaanxi Key Laboratory of Preventinon and Therapy of Cerebral Disease, Xi'an Medical University, No. 1 Xinwang Road, Xi'an, 710016, Shaanxi, China. zhangyuelin68@163.com. 7. Department of Neurosurgery, Wuhan General Hospital of PLA, No. 627 Wuluo Road, Wuhan, 430070, Hubei, China. 1196796625@qq.com.
Abstract
PURPOSE: Accumulating evidence indicates that dysregulated long noncoding RNAs (lncRNAs) play critical roles in tumorigenesis and cancer progression. LncRNA-maternally expressed gene 3 (MEG3) has been shown to be involved in the initiation and development of several cancers, including glioma. However, the clinical prognostic value of MEG3 in glioma has not yet been fully elucidated. METHODS: The expression levels of MEG3 were detected in 79 glioma tissues and adjacent normal brain tissues, as well as, glioma cells and normal human astrocytes by qRT-PCR. Kaplan-Meier and Cox regression methods were utilized for the survival analysis. MTT assay, flow cytometry, and immunofluorescence assay were carried out to detect the impact of MEG3 on glioma cell proliferation, apoptosis, and autophagy. RESULT: The current results showed that MEG3 expression was significantly downregulated in glioma tissues and cell line and negatively correlated with WHO grade in glioma patients. Low MEG3 expression was significantly associated with the advanced WHO grade, low Karnofsky performance score (KPS), IDH wild-type, and tumor recurrence. Patients displaying a low expression of MEG3 contributed to poor overall survival. The downregulated level of MEG3, advanced WHO grade, low KPS, IDH wild-type, and tumor recurrence were independent poor prognostic indicators in glioma patients. The in vitro experiments demonstrated that the MEG3 overexpression remarkably suppressed the proliferation while facilitating apoptosis and autophagy in glioma cells. CONCLUSIONS: These findings indicated a critical role of MEG3 in glioma cell proliferation, apoptosis, and autophagy. Also, the gene was found to be significantly associated with the prognosis in glioma patients. Thus, it might provide a new target for predicting prognosis and therapeutic intervention in glioma.
PURPOSE: Accumulating evidence indicates that dysregulated long noncoding RNAs (lncRNAs) play critical roles in tumorigenesis and cancer progression. LncRNA-maternally expressed gene 3 (MEG3) has been shown to be involved in the initiation and development of several cancers, including glioma. However, the clinical prognostic value of MEG3 in glioma has not yet been fully elucidated. METHODS: The expression levels of MEG3 were detected in 79 glioma tissues and adjacent normal brain tissues, as well as, glioma cells and normal human astrocytes by qRT-PCR. Kaplan-Meier and Cox regression methods were utilized for the survival analysis. MTT assay, flow cytometry, and immunofluorescence assay were carried out to detect the impact of MEG3 on glioma cell proliferation, apoptosis, and autophagy. RESULT: The current results showed that MEG3 expression was significantly downregulated in glioma tissues and cell line and negatively correlated with WHO grade in gliomapatients. Low MEG3 expression was significantly associated with the advanced WHO grade, low Karnofsky performance score (KPS), IDH wild-type, and tumor recurrence. Patients displaying a low expression of MEG3 contributed to poor overall survival. The downregulated level of MEG3, advanced WHO grade, low KPS, IDH wild-type, and tumor recurrence were independent poor prognostic indicators in gliomapatients. The in vitro experiments demonstrated that the MEG3 overexpression remarkably suppressed the proliferation while facilitating apoptosis and autophagy in glioma cells. CONCLUSIONS: These findings indicated a critical role of MEG3 in glioma cell proliferation, apoptosis, and autophagy. Also, the gene was found to be significantly associated with the prognosis in gliomapatients. Thus, it might provide a new target for predicting prognosis and therapeutic intervention in glioma.
Authors: Lei Hu; Qiao-Li Lv; Shu-Hui Chen; Bao Sun; Qiang Qu; Lin Cheng; Ying Guo; Hong-Hao Zhou; Lan Fan Journal: Int J Environ Res Public Health Date: 2016-04-19 Impact factor: 3.390
Authors: Carlos Deocesano-Pereira; Raquel Arminda Carvalho Machado; Henrique Cesar De Jesus-Ferreira; Thiago Marchini; Tulio Felipe Pereira; Ana Claudia Oliveira Carreira; Mari Cleide Sogayar Journal: Oncol Lett Date: 2019-10-08 Impact factor: 2.967